Weekly Digest - January 2025
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - January 2025
20 Jan 2025: GI Innovation, LaNova Medicines sign MOU to develop combination therapy for pancreatic cancer
- GI Innovation & LaNova signed MOU to develop a pancreatic cancer combination therapy with the immuno-oncology drug GI-102 and ADC LM-302 targeting Claudin18.2
- Preclinical models for pancreatic cancer showed promising anti-cancer activity
- LaNova is known for licensing LM-305 to AstraZeneca for 800 billion and LM-299 to MSD for 4.6 trillion
- GI-102 enhances immune memory and LM-302 destroys tumor cells, improving response and survival
- The collaboration aims to advance clinical development of the combination therapy for advanced pancreatic cancer patients
